Image

Ketogenic Diet and Neuromodulation in Treatment Resistant Depression

Ketogenic Diet and Neuromodulation in Treatment Resistant Depression

Recruiting
18-65 years
All
Phase N/A

Powered by AI

Overview

The goal of this clinical trial is to learn if combining a ketogenic diet with a personalized, accelerated brain stimulation treatment (iTBS) works better than iTBS with a standard healthy diet to reduce depression symptoms in adults with treatment-resistant depression. The main questions it aims to answer are:

  • Does iTBS combined with a ketogenic diet improve depression symptoms more than iTBS combined with a standard healthy diet?
  • Does the ketogenic diet change ketone levels over time?
  • Is it safe, tolerable, and feasible to follow a ketogenic diet during accelerated iTBS treatment?

We will compare a ketogenic diet to a Canadian Food Guide-aligned diet, both combined with iTBS, measuring depression severity using standard clinician-rated and self-report scales.

Participants will:

  • Follow either a ketogenic diet or a standard healthy diet for 12 weeks, starting with a 3-week lead-in period before iTBS begins
  • Undergo a course of personalized, imaging-guided accelerated iTBS while continuing their assigned diet
  • Complete clinical and cognitive assessments, blood tests, and brain MRI scans before and after treatment
  • Have their ketone levels checked regularly throughout the 12-week period

Eligibility

Inclusion Criteria:

  • Age 18-65 of any sex, gender identity, ethnicity and socioeconomic status
  • Currently experiencing a major depressive episode as defined by DSM-5-TR criteria and confirmed by a study physician
  • Presenting with at least moderate symptom severity (PHQ ≥ 10)
  • Meeting criteria for treatment-resistant depression (TRD), defined as either: (1) failure to achieve a clinical response to ≥2 adequate antidepressant treatment trials for unipolar depression, OR (2) inability to tolerate ≥2 separate antidepressant treatment trials for unipolar depression, as assessed using the Antidepressant Treatment History Form (ATHF), with a score of ≥3 in the current episode
  • No rTMS treatment received in the current depressive episode (prior rTMS in a previous episode is permitted); no failure to respond to a course of electroconvulsive therapy (ECT) in the current depressive episode
  • Able to provide informed consent
  • Available for the 12-week intervention and willing to follow either a ketogenic or Canadian Food Guide-aligned diet
  • No increase or initiation of any antidepressant or antipsychotic medication in the 4 weeks prior to screening

Exclusion Criteria:

  • Concomitant major unstable medical illness as determined by a study physician
  • Lifetime diagnosis of bipolar I or bipolar II disorder, or a primary psychotic disorder, as confirmed by a structured psychiatric interview
  • Current psychotic symptoms
  • Diagnosis of obsessive-compulsive disorder, post-traumatic stress disorder (current or within the last year), anxiety disorder (generalised anxiety disorder, social anxiety disorder, panic disorder), or dysthymia, assessed by a study investigator to be primary and causing greater impairment than MDD
  • Diagnosis of any personality disorder assessed by a study investigator to be primary and/or causing greater impairment than MDD
  • History of epilepsy, stroke, or major neurological conditions, or a history of a primary seizure disorder or a seizure associated with an intracranial lesion
  • Physical or cognitive disability interfering with participation
  • Pregnancy, nursing, or intent to become pregnant during study
  • BMI \< 20 kg/m²
  • Suicide attempts in the past 12 months
  • Active suicidal intent as confirmed by study psychiatrist
  • Active eating disorder in the past 12 months
  • Currently following a Ketogenic diet
  • Habitual low-carb diet in the past 6 months
  • GI disorders or food allergies incompatible with dietary protocols
  • Alcohol use \>3 drinks/day or \>14/week
  • Use of anticonvulsants (benzodiazepines with a dose of \<2 lorazepam equivalents will be permitted), GABA agonists, or medications reducing TMS efficacy
  • Contraindications to MRI
  • Unwillingness to perform daily finger-stick testing
  • Inability to access or prepare KD-compliant foods if assigned
  • Unable to provide informed consent on their own

Study details
    Major Depressive Disorder (MDD)
    Treatment Resistant Depression (TRD)

NCT07376018

Sunnybrook Health Sciences Centre

31 October 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.